Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

Market outlook of the epilepsy drugs market in Europe

Epilepsy is a group of varying disorders that has life-threatening symptoms. It is generally caused by brain deformities and is characterized by the frequent occurrence of generalized or partial seizures. The market for epilepsy drugs in Europe is positively influenced by the adoption of reformulation strategies by vendors and is expected to surpass US$ 1,100 million by 2019.

In this market research report, analysts have estimated factors like the unmet medical needs of patients in Europe to positively drive market growth during the forecast period. At present, the drugs that are administered during epilepsy fail drastically to check the progression of the disease and may lead to complications like weight gain, blurred vision, and dizziness. The unavailability of effective drugs for treating epilepsy will provide vendors the opportunity to design effective disease-modifying therapies that will spur market growth.        

Segmentation by generation of drugs and analysis of the epilepsy drugs market in Europe

• First generation
• Second generation
• Third generation

First-generation anti-epileptic drugs include compounds like benzodiazepines, carbamazepine, and phenytoin. Drugs like phenytoin function by inducing the CYP enzyme, which then triggers drug-drug interactions. However, these drugs have to be monitored closely and may often lead to life-threatening reactions.

Competitive landscape and key vendors

This market is dominated by large vendors like Eisai, GlaxoSmithKline, Pfizer, and UCB. The recent increase in patient population and the expected launch of promising pipeline drugs during the forecast period are expected to spur the revenues generated by the companies.

Leading vendors in this market are –

• Eisai
• UCB Pharma
• Pfizer
• GlaxoSmithKline

Other prominent vendors in this market are AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, and Valeant Pharmaceuticals.

Growth drivers, challenges, and upcoming trends: Epilepsy Drugs

Upcoming trends like the advent of new-generation anti-epileptic drugs is expected to foster market growth as they have a superior pharmacokinetic profile when compared to conventional drugs. As these drugs have little or no side effects, they are rapidly gaining acceptance in various territories.

This report provides a number of factors contributing to the adoption, limitations, and opportunities of the epilepsy drugs market in Europe. It also offers an analysis of each factor and an estimation of the extent to which the factors are likely to impact the overall market growth.

Key questions answered in the report include

• What will the market size and the growth rate be in 2019?
• What are the key factors driving the epilepsy drugs market in Europe?
• What are the trends impacting the growth of the epilepsy drugs market in Europe?
• What are the challenges to market growth?
• Who are the key vendors in the epilepsy drugs market in Europe?
• What are the market opportunities and threats faced by the vendors in the epilepsy drugs market in Europe?
• What are the key outcomes of the five forces analysis of the epilepsy drugs market in Europe?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Epilepsy Market 2014-2018
• Epilepsy Market in the US 2015-2019
• Epilepsy Therapeutics Market in the APAC Region 2015-2019